tiprankstipranks
Healthpeak Properties, Inc. (DOC)
NYSE:DOC
Want to see DOC full AI Analyst Report?

Healthpeak Properties (DOC) AI Stock Analysis

1,537 Followers

Top Page

DOC

Healthpeak Properties

(NYSE:DOC)

Select Model
Select Model
Select Model
Neutral 62 (OpenAI - 5.2)
Rating:62Neutral
Price Target:
$23.00
â–²(3.28% Upside)
Action:Reiterated
Date:08/06/26
DOC scores in the low-60s primarily due to mid-tier financial statement quality (margin volatility and weaker recent free-cash-flow momentum offsetting improved leverage) and a supportive earnings-call backdrop (raised FFO guidance, strong liquidity and capital recycling). Technicals are moderately constructive, while valuation is held back by a very high P/E despite an attractive dividend yield.
Positive Factors
Balance sheet and liquidity
Lower leverage and large available liquidity materially improve financial flexibility for a REIT with development and capital recycling needs. Sustained sub-5x net debt/EBITDA and ample cash reduce refinancing risk, enable opportunistic buybacks or JV capital and support dividend coverage over the next several quarters.
Negative Factors
Lab occupancy gap
Lab space recovery remains incomplete and requires net absorption to drive NOI inflection. Long leasing cycles, tenant diligence, and conversion time mean lab cash flows could lag other portfolio segments for many quarters, constraining overall portfolio NOI upside and rent roll stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet and liquidity
Lower leverage and large available liquidity materially improve financial flexibility for a REIT with development and capital recycling needs. Sustained sub-5x net debt/EBITDA and ample cash reduce refinancing risk, enable opportunistic buybacks or JV capital and support dividend coverage over the next several quarters.
Read all positive factors

Healthpeak Properties Key Performance Indicators (KPIs)

Any
Any
Net Income by Segment
Net Income by Segment
Shows profit or loss after all expenses and non‑operating items for each segment. Variations can reflect operating performance, property sales, or one‑time charges, so this helps identify which segments are actually contributing to reported earnings versus being affected by accounting or transaction noise.
Chart InsightsOutpatient medical and senior housing have shifted from background contributors to the primary drivers of net income growth—outpatient acceleration reflects strong leasing fundamentals while senior housing flipped to sustained profitability following the Janus Living IPO (monetization optionality and eventual ~ $0.04/sh accretion). Lab remains the noisy swing factor—historical one‑offs and a sharp 2025 Q3 hit highlight downside from softer re‑leasing spreads. Corporate costs and upcoming refinancing (mid‑2026 maturities) are the main near‑term earnings drags to monitor.
Data provided by:The Fly

Healthpeak Properties (DOC) vs. SPDR S&P 500 ETF (SPY)

Healthpeak Properties Business Overview & Revenue Model

Company Description
Healthpeak Properties, Inc. (DOC) is a publicly traded real estate investment trust (REIT) that owns, operates, and develops healthcare-related real estate in the United States. The company focuses on three primary property sectors: life science (...
How the Company Makes Money
Healthpeak makes money primarily by generating rental and property-related income from its healthcare real estate portfolio. Key revenue streams typically include: (1) Lease income from life science and medical office properties, where tenants (e....

Healthpeak Properties Earnings Call Summary

Earnings Call Date:Aug 04, 2026
(Q2-2026)
|
% Change Since: |
Next Earnings Date:Oct 22, 2026
Earnings Call Sentiment Positive
The call highlighted meaningful operational progress: strong balance sheet metrics (net debt/EBITDA 4.7x), sizable liquidity, large JV partnerships (Brookfield/Blackstone) that raise $1B+ in proceeds while preserving control, strong outpatient leasing (1.2M SF in Q2; occupancy to 90.7%), lab leasing momentum and occupancy improvement (78.5%, +140 bps YTD), and significant senior housing/Janus performance (45% revenue growth, 34% adjusted EBITDA growth). Challenges remain, notably lab occupancy still below peak, selective elevated CapEx needs for redevelopments, elevated borrowing costs limiting leverage options, cautious tenant timelines, and only a modest FFO guidance raise. Overall the positive operational momentum, strategic partnerships, and strong liquidity and balance sheet outweigh the remaining execution and market risks.
Positive Updates
Strong Balance Sheet and Liquidity
Net debt to adjusted EBITDA of 4.7x (below 5x), $4.1 billion of available liquidity, $900 million of debt repaid through Aug 4 (including $650 million of senior unsecured notes in July), and guidance that the company can maintain leverage below its 5.5x long-term target.
Negative Updates
Lab Occupancy Still Below Target
Lab total occupancy is 78.5%, improving but still materially below outpatient levels; management said same-store inflection timing is unclear and continued net absorption will be required to drive NOI inflection.
Read all updates
Q2-2026 Updates
Negative
Strong Balance Sheet and Liquidity
Net debt to adjusted EBITDA of 4.7x (below 5x), $4.1 billion of available liquidity, $900 million of debt repaid through Aug 4 (including $650 million of senior unsecured notes in July), and guidance that the company can maintain leverage below its 5.5x long-term target.
Read all positive updates
Company Guidance
On guidance, Healthpeak raised full‑year FFO as adjusted by $0.02 to $1.73–$1.77 per share, driven by a 75‑basis‑point increase in total same‑store NOI at the midpoint (including +200 bps each for lab and senior housing) and recognition of lower market interest amortization tied to a $400 million seller‑note repayment; the company reported Q2 FFO as adjusted of $0.46, ended the quarter with net debt/adjusted EBITDA of 4.7x (leverage below 5x vs. a 5.5x long‑term target), expects roughly $1.9 billion of gross capital‑recycling proceeds through year‑end, has completed $1.0 billion of acquisitions and buybacks to date, repaid $900 million of debt (including $650 million of senior notes in July), holds $4.1 billion of available liquidity, and cited ongoing optionality to deploy capital into preleased outpatient development, JV acquisitions, or opportunistic buybacks (having repurchased $100 million in April at a >10% FFO yield when the stock was under $17).

Healthpeak Properties Financial Statement Overview

Summary
Middle-tier fundamentals: steady but modest revenue growth, improved leverage profile in TTM, but notable profitability/margin volatility (especially the unusually low TTM gross margin) and sharply negative TTM free-cash-flow growth reduce confidence in earnings quality and cash-flow consistency.
Income Statement
58
Neutral
Balance Sheet
63
Positive
Cash Flow
55
Neutral
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.95B2.82B2.70B2.18B2.06B1.90B
Gross Profit74.71M634.55M1.63B1.28B1.20B1.12B
EBITDA1.78B1.47B1.61B1.27B1.39B970.63M
Net Income253.72M71.35M243.14M306.01M500.45M505.54M
Balance Sheet
Total Assets21.68B20.34B19.94B15.70B15.77B15.26B
Cash, Cash Equivalents and Short-Term Investments1.63B537.70M119.82M117.64M72.03M158.29M
Total Debt10.32B10.44B9.02B7.08B6.71B6.37B
Total Liabilities12.18B12.03B10.88B8.77B8.48B8.11B
Stockholders Equity7.84B7.50B8.40B6.35B6.65B6.52B
Cash Flow
Free Cash Flow296.21M1.25B1.07B956.24M900.26M795.25M
Operating Cash Flow1.23B1.25B1.07B956.24M900.26M795.25M
Investing Cash Flow-1.10B-1.03B-113.80M-576.75M-876.34M531.03M
Financing Cash Flow1.42B136.11M-941.42M-337.30M-116.53M-1.29B

Healthpeak Properties Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price22.27
Price Trends
50DMA
21.22
Negative
100DMA
19.36
Positive
200DMA
17.96
Positive
Market Momentum
MACD
-0.18
Positive
RSI
41.42
Neutral
STOCH
14.60
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DOC, the sentiment is Neutral. The current price of 22.27 is above the 20-day moving average (MA) of 21.72, above the 50-day MA of 21.22, and above the 200-day MA of 17.96, indicating a neutral trend. The MACD of -0.18 indicates Positive momentum. The RSI at 41.42 is Neutral, neither overbought nor oversold. The STOCH value of 14.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DOC.

Healthpeak Properties Risk Analysis

Healthpeak Properties disclosed 58 risk factors in its most recent earnings report. Healthpeak Properties reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Healthpeak Properties Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
$13.94B16.1016.51%5.18%15.18%72.69%
71
Outperform
$3.50B21.0210.96%4.57%23.77%10.04%
65
Neutral
$2.17B12.193.79%4.94%3.15%1.96%
65
Neutral
$5.15B76.972.34%5.37%18.43%-65.50%
63
Neutral
$6.58B-73.39-1.94%4.49%-6.28%77.63%
62
Neutral
$14.70B59.403.30%5.48%5.52%48.98%
* Real Estate Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DOC
Healthpeak Properties
20.79
4.61
28.50%
NHI
National Health Investors
72.95
1.71
2.40%
OHI
Omega Healthcare
46.53
7.87
20.34%
SBRA
Sabra Healthcare REIT
20.32
2.94
16.93%
HR
Healthcare Realty Trust
19.25
3.59
22.96%

Healthpeak Properties Corporate Events

Business Operations and StrategyStock BuybackFinancial DisclosuresPrivate Placements and Financing
Healthpeak Properties Reports Strong Q2 Results, Capital Actions
Positive
Aug 4, 2026
On August 4, 2026, Healthpeak Properties reported second-quarter 2026 diluted net income of $0.08 per share and FFO as Adjusted of $0.46 per share, alongside modest same-store NOI growth led by senior housing and higher occupancy in its outpatient...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 06, 2026